Cooper Companies Inc
Research Cooper Companies Inc (COO) on Bullrun: valuation model: 37.3% overvalued, market cap USD 14.24B, P/E 61.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCOO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyUSD
- Valuation signal37.3% overvalued
- Market capUSD 14.24B
- P/E61.7
- Financial periodQ2 2026
- RevenueUSD 1.08B
- Net income-USD 77.90M
- Free cash flowUSD 96.40M
- Gross margin68.0%
Valuation Snapshot
Bullrun's latest valuation model marks Cooper Companies Inc as 37.3% overvalued; latest market cap is USD 14.24B; P/E is 61.7.
Peer valuation comparison
Latest P/E is 61.68x versus a Healthcare sector median of 24.46x (152.2% above).
Latest P/E is 61.68x versus a United States median of 24.87x (148.1% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.09B | USD 374.90M | USD 433.70M | 65.5% | 1.87 | USD 110.60M | USD 2.50B | USD 8.24B |
| FY2024 | USD 3.90B | USD 392.30M | USD 288.10M | 66.6% | 1.96 | USD 107.60M | USD 2.58B | USD 8.08B |
| FY2023 | USD 3.59B | USD 294.20M | USD 215.00M | 65.6% | 1.48 | USD 120.80M | USD 2.57B | USD 7.55B |
| FY2022 | USD 3.31B | USD 385.80M | USD 450.40M | 64.7% | 1.94 | USD 138.20M | USD 2.76B | USD 7.17B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 14.24B | 61.7 | n/a | n/a |
| 2025 | 2025-12-31 | USD 16.06B | 43.8 | n/a | n/a |
| 2024 | 2024-12-31 | USD 18.35B | 46.9 | n/a | n/a |
| 2023 | 2023-12-29 | USD 18.74B | 63.9 | 0.0% | 0.02 |
| 2022 | 2022-12-30 | USD 16.32B | 42.6 | 0.0% | 0.02 |
| 2021 | 2021-12-31 | USD 20.70B | 7.1 | 0.0% | 0.02 |
Dividend history
| Year | Dividends/share |
|---|---|
| FY2023 | 0.01 USD |
| FY2022 | 0.01 USD |
About Cooper Companies Inc
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Cooper Companies Inc overvalued or undervalued?
Bullrun's valuation model currently marks Cooper Companies Inc as 37.3% overvalued.
What is Cooper Companies Inc's market cap?
Cooper Companies Inc's market capitalization is USD 14.24B.
What is Cooper Companies Inc's P/E ratio?
Cooper Companies Inc's price-to-earnings (P/E) ratio is 61.7.
What does Cooper Companies Inc do?
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage.